Rita Onyebuchi Ogboh

Rita Onyebuchi Ogboh

Auto-generated profile, based on publicly available information

Rita Onyebuchi Ogboh

Department of Pharmacology and Toxicology, Niger Delta University, Yenagoa, Nigeria

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2026 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Closed access
RORita Onyebuchi Ogboh
Rita Onyebuchi Ogboh
EBEjembi Bright
Ejembi Bright
AEAdebola Ayisat Effa
Adebola Ayisat Effa
BOBlessing Chinonye Okoro
Blessing Chinonye Okoro
AAAnthony Kosisochukwu Anyabuoke
Anthony Kosisochukwu Anyabuoke
Prostate cancer still remains one of the most common cancers in men worldwide, and it is a great therapeutic challenge, especially in the field of immunotherapeutics. The tumour microenvironment (TME) is immunologically “cold” in prostate cancer, and influenced by intrinsic molecular characteristics of the disease such as androgen receptor (AR) signalling, PTEN loss, and lineage plasticity towards neuroendocrine prostate cancer (NEPC). Together, these aspects inhibit antigen presentation, block the entry of cytotoxic T cells and help to establish spatially organised immunosuppressive niches, providing a rational explanation for the clinical variability and partial efficacy of immune-based therapies. Traditional bulk genomic approaches have provided important insights into tumour biology but are unable to capture the cellular and spatial complexity of tumour–immune interactions. These developments have been spurred by recent advancements in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, which allow to detect individual cell subpopulations within intact tumour tissues, such as exhausted T cells co-expressing PD-1, TIM-3, LAG-3 and TIGIT, immunosuppressive SPP1+ macrophages and various cancer-associated fibroblast subpopulations. These technologies have identified specific immune exclusion sites, stromal–epithelial immune silencing barriers, and therapeutic resistance and immune evasion regulatory programs in the context of prostate cancer specifically. However, there are still many technical challenges that need to be overcome, such as the lack of patient samples and their demographic diversity, data integration, lack of spatial characterisation of bone metastases and difficulties in clinical translation. Comprehensive multi-omics atlases, AI-driven spatial pattern recognition, functional validation of potential targets and prospective clinical trials based on biomarkers are all important areas for future research. They show significant potential for the creation of better, personalized immunotherapeutic treatment for prostate cancer.

17 March 2026 in Journal of International Research in Medical and Pharmaceutical Sciences
Verified
Journal Article
Closed access
OOOgboh Rita Onyebuchi
Ogboh Rita Onyebuchi
OAOlukunle O. Akanbi
Olukunle O. Akanbi
AOAdepeju Kafayat Olowookere
Adepeju Kafayat Olowookere
IBIsaac Baiden
Isaac Baiden
FNFaith Chinaza Ngwoke
Faith Chinaza Ngwoke
UOUchechukwu Lilian Okoye
Uchechukwu Lilian Okoye
The increasing global burden of disease, rising research and development costs, and high attrition rates in pharmaceutical pipelines underscore the need for more efficient approaches to therapeutic development and drug safety monitoring. Artificial intelligence (AI) and machine learning (ML) have emerged as data-driven tools with the potential to improve multiple stages of the pharmaceutical lifecycle. This narrative review is designed to provide a structured and critical overview of the use of AI and ML in drug discovery and drug safety surveillance. A comprehensive literature search was performed to identify relevant studies using major electronic databases, with emphasis on publications from 1997 to March 2025. The studies were selected based on the inclusion criteria. The findings of the study show that AI and ML are being used in drug discovery, drug development, and drug safety surveillance. These technologies have the potential to provide predictive models, integrate heterogeneous biomedical data, and analyze real-world data to detect adverse drug reactions. Deep learning and natural language processing have been found to be useful tools to improve early risk detection. However, some limitations have also been found. These include the quality of the data, bias in AI and ML models, lack of interpretability of AI and ML models, lack of external validation, and lack of real-world implementation. These limitations need to be addressed to make AI and ML more useful tools for drug discovery and drug safety surveillance. Overall, while AI and ML offer meaningful opportunities to enhance drug discovery and pharmacovigilance, their impact remains dependent on rigorous validation, improved data governance, and alignment with clinical and regulatory frameworks. Continued research and context-specific implementation strategies will be essential to support their effective and equitable integration into pharmaceutical research and healthcare systems.

27 May 2026 in Journal of Advances in Food Science & Technology
Verified
Journal Article
Closed access
PKPatience Awewoli Kwara
Patience Awewoli Kwara
CEChisom Ejezie
Chisom Ejezie
RORita Onyebuchi Ogboh
Rita Onyebuchi Ogboh
Rising atmospheric carbon dioxide (CO₂) is increasingly recognized as a determinant of crop nutritional quality, with implications that extend beyond yield alone. This review brings together mechanistic, experimental, and epidemiological evidence to examine how elevated CO₂ alters the micronutrient composition of staple crops and what this means for population health. Drawing on plant physiology, field-based enrichment studies, controlled experiments, and dietary modeling, it outlines the pathways through which atmospheric change influences food quality. Elevated CO₂ enhances carbon assimilation and promotes the accumulation of carbohydrates, leading to a relative dilution of other nutrients. At the same time, reduced transpiration and changes in nitrogen metabolism constrain the uptake and incorporation of key nutrients, including iron, zinc, protein, and selected vitamins, particularly in major crops such as rice and wheat. Across different study designs, a consistent pattern emerges, with declines in nutrient density shaped by crop type, genotype, and environmental conditions. For populations that rely heavily on staple foods, these changes translate into lower dietary intake of essential micronutrients. Model-based projections suggest that continued increases in CO₂ could substantially increase the global burden of iron and zinc deficiencies by mid-century. Taken together, the evidence points to a widening gap between food quantity and food quality. Addressing this challenge will require coordinated approaches that link crop improvement, soil and agronomic management, dietary diversification, and nutrition-sensitive policy within broader climate and food system strategies.